468 related articles for article (PubMed ID: 23179944)
1. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
Nayak B; Dogra PN; Naswa N; Kumar R
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
[TBL] [Abstract][Full Text] [Related]
2. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
3. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.
Goodfellow H; Viney Z; Hughes P; Rankin S; Rottenberg G; Hughes S; Evison F; Dasgupta P; O'Brien T; Khan MS
BJU Int; 2014 Sep; 114(3):389-95. PubMed ID: 24341486
[TBL] [Abstract][Full Text] [Related]
4. [Value of dual-phase (18)F-FDG PET/CT in preoperative staging of bladder cancer].
Li H; Wu H; Wang Q; Han Y; Wang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Apr; 34(4):500-3. PubMed ID: 24752096
[TBL] [Abstract][Full Text] [Related]
5. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
6. Dual phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer.
Yildirim-Poyraz N; Ozdemir E; Uzun B; Turkolmez S
Rev Esp Med Nucl Imagen Mol; 2013; 32(4):214-21. PubMed ID: 23218514
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
[TBL] [Abstract][Full Text] [Related]
8. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
[TBL] [Abstract][Full Text] [Related]
9. Commentary on "Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle." Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam Hospital, Amsterdam, The Netherlands.: BJU Int 2013; 112(6):72934. doi:10.1111/bju.12109. [Epub 2013 Jun 24].
See WA
Urol Oncol; 2014 Nov; 32(8):1350. PubMed ID: 25488385
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
11. Pelvic Lymph Node Staging by Combined
Pichler R; De Zordo T; Fritz J; Kroiss A; Aigner F; Heidegger I; Virgolini I; Horninger W; Uprimny C
Clin Genitourin Cancer; 2017 Jun; 15(3):e387-e395. PubMed ID: 27601364
[TBL] [Abstract][Full Text] [Related]
12. Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer?
Uttam M; Pravin N; Anish B; Nandita K; Arup M
Int Braz J Urol; 2016; 42(2):234-41. PubMed ID: 27256176
[TBL] [Abstract][Full Text] [Related]
13. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and
Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J
Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of
Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience.
Shahait M; Abu-Hijlih R; Farkouh A; Obeidat S; Salah S; Abdlkadir AS; Al-Ibraheem A
J Egypt Natl Canc Inst; 2023 Jul; 35(1):21. PubMed ID: 37455263
[TBL] [Abstract][Full Text] [Related]
16. FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy.
Jeong IG; Hong S; You D; Hong JH; Ahn H; Kim CS
Ann Surg Oncol; 2015 Sep; 22(9):3150-6. PubMed ID: 25634779
[TBL] [Abstract][Full Text] [Related]
17. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.
Kibel AS; Dehdashti F; Katz MD; Klim AP; Grubb RL; Humphrey PA; Siegel C; Cao D; Gao F; Siegel BA
J Clin Oncol; 2009 Sep; 27(26):4314-20. PubMed ID: 19652070
[TBL] [Abstract][Full Text] [Related]
19. [(18)F]Fluorodeoxyglucose - positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy.
Kollberg P; Almquist H; Bläckberg M; Cronberg C; Garpered S; Gudjonsson S; Kleist J; Lyttkens K; Patschan O; Liedberg F
Scand J Urol; 2015; 49(4):296-301. PubMed ID: 25623843
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
